All In Biotech

Drug Trial Radar · NCT00545584

Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy

Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,512 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,512

Actual

Start

Apr 1, 2007

Primary completion

Nov 19, 2009

Study completion Nov 19, 2009

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c \[HbA1c\] 6.5-9%). A difference between the three strategies of lifestyle changes was expected.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

  • sitagliptin phosphateDrug

    sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks

  • Comparator: DietBehavioral

    Diet

  • Comparator: Physical ActivityBehavioral

    Physical Activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin A1c MeasurementTime frame: Baseline and Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.